Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineage
Nature Communications·
- DOI
- 10.1038/s41467-024-52668-w
- PMID
- 39362845
- PMCID
- PMC11450198
- OpenAlex
- W4403083173
- Study type
- Journal article
- Publisher
- Springer Science and Business Media LLC
- Article type
- journal-article
- Integrity
- current
Publication version
This article has a linked preprint
The relationship comes from Crossref version metadata. Compare both records because findings and wording may have changed between versions.
Open linked preprint →Why this research matters now
The findings indicate immune escape likely contributed to JN.1 emergence despite high population immunity, while infections with this lineage appeared less likely to result in clinically severe disease. The study underscores the ongoing need to monitor immune escape and clinical severity in emerging SARS-CoV-2 variants to inform public health responses.
Structured evidence summary
Research question
The study examined epidemiological characteristics and clinical outcomes associated with SARS-CoV-2 BA.2.86/JN.1 lineage infections compared to co-circulating XBB-derived lineage infections during the winter 2023-24 surge in the United States.
Study design
Time-matched comparison of cases infected with BA.2.86 lineages versus XBB-derived lineages during December 2023 and January 2024, with sensitivity analyses conducted to assess potential under-ascertainment of prior infections.
Population and setting
COVID-19 cases in the United States during December 2023 and January 2024, when BA.2.86 lineages (predominantly JN.1) achieved widespread transmission alongside XBB-derived lineages.
Main findings
Individuals infected with BA.2.86 lineages had received more COVID-19 vaccine doses, including XBB.1.5-targeted boosters, and had more documented prior infections compared to those infected with XBB-derived lineages. BA.2.86 lineage infections were associated with lower risk of progression to severe outcomes requiring emergency department visits or hospitalization.
Public-health relevance
The findings indicate immune escape likely contributed to JN.1 emergence despite high population immunity, while infections with this lineage appeared less likely to result in clinically severe disease. The study underscores the ongoing need to monitor immune escape and clinical severity in emerging SARS-CoV-2 variants to inform public health responses.
Important limitations
This summary is limited to the supplied single-article abstract and metadata. Decision-grade interpretation requires review of the original paper, including detailed methods, case definitions, adjustment for confounding factors, and complete results.
GIDS interpretation
The article was classified under outbreak investigation, transmission dynamics, and vaccination topics for COVID-19 and SARS in the United States. These links support discoverability within surveillance and epidemiological literature collections but do not themselves constitute evidence of a current public health signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 11 auditable classifier relationships to diseases, places, topics, and study design.